Literature DB >> 32645698

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype.

Yousif A Kariri1,2,3, Mohammed A Aleskandarany1, Chitra Joseph1, Sasagu Kurozumi1, Omar J Mohammed3, Michael S Toss1, Andrew R Green1,3, Emad A Rakha4.   

Abstract

Lymphovascular invasion (LVI) is associated with poor outcome in breast cancer (BC); however, its underlying mechanisms remain ill-defined. LVI in BC develops through complex molecular pathways involving not only the interplay with the surrounding microenvironment along with endothelial cells lining the lymphovascular spaces but also changes in the malignant epithelial cells with the acquisition of more invasive and migration abilities. In this review, we focus on the key features that enable tumour cell detachment from the primary niche, their migration and interaction with the surrounding microenvironment as well as the crosstalk with the vascular endothelial cells, which eventually lead to intravasation of tumour cells and LVI. Intravascular tumour cell survival and migration, their distant site extravasation, stromal invasion and growth are part of the metastatic cascade. Cancer cell migration commences with loss of tumour cells' cohesion initiating the invasion and migration processes which are usually accompanied by the accumulation of specific cellular and molecular changes that enable tumour cells to overcome the blockades of the extracellular matrix, spread into surrounding tissues and interact with stromal cells and immune cells. Thereafter, tumour cells migrate further via interacting with lymphovascular endothelial cells to penetrate the vessel wall leading ultimately to intravasation of cancer cells. Exploring the potential factors influencing cell migration in LVI can help in understanding the underlying mechanisms of LVI to identify targeted therapy in BC.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Cancer stem cells; Cell migration; Molecular mechanisms; Vascular invasion

Mesh:

Year:  2020        PMID: 32645698     DOI: 10.1159/000508337

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  7 in total

1.  An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer.

Authors:  Reiki Nishimura; Tomofumi Osako; Yasuhiro Okumura; Masahiro Nakano; Hiroko Ohtsuka; Mamiko Fujisue; Nobuyuki Arima
Journal:  Oncol Lett       Date:  2022-06-07       Impact factor: 3.111

2.  Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.

Authors:  Della Makower; Juan Lin; Xiaonan Xue; Joseph A Sparano
Journal:  NPJ Breast Cancer       Date:  2021-03-01

3.  The Presence of Yin-Yang Effects in the Migration Pattern of Staurosporine-Treated Single versus Collective Breast Carcinoma Cells.

Authors:  Frank A H Meyer; Dominik Kraus; Alexander Glassmann; Nadine Veit; Jochen Winter; Rainer Probstmeier
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

4.  Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.

Authors:  Yousif Kariri; Michael S Toss; Mansour Alsaleem; Khloud A Elsharawy; Chitra Joseph; Nigel P Mongan; Andrew R Green; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2022-02-06       Impact factor: 4.872

5.  Correlation Analysis of Pathological Features and Axillary Lymph Node Metastasis in Patients with Invasive Breast Cancer.

Authors:  Hongye Chen; Xiangchao Meng; Xiaopeng Hao; Qiao Li; Lin Tian; Yue Qiu; Yuhui Chen
Journal:  J Immunol Res       Date:  2022-09-19       Impact factor: 4.493

6.  HOXB7 Overexpression Leads Triple-Negative Breast Cancer Cells to a Less Aggressive Phenotype.

Authors:  Simone Aparecida de Bessa Garcia; Mafalda Araújo; Tiago Pereira; Renata Freitas
Journal:  Biomedicines       Date:  2021-05-05

Review 7.  Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer.

Authors:  Jia-Mei Chen; Bo Luo; Ru Ma; Xi-Xi Luo; Yong-Shun Chen; Yan Li
Journal:  Diagnostics (Basel)       Date:  2021-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.